Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United TherapeuticsUTHR -0.73%88 EV-to-EBITDA is 11.15 as of Jul. 28, 2026, which is 56% above its 10-year median of 7.14. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $387.24 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 743 Drug Manufacturers companies, United Therapeutics ranks better than 55.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, United Therapeutics's enterprise value is $19,105 Mil.
United Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1,714 Mil. Therefore, United Therapeutics's EV-to-EBITDA for today is 11.15.
The historical rank and industry rank for United Therapeutics's EV-to-EBITDA or its related term are showing as below:
UTHR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -59.7 Med: 7.14 Max: 15.27
Current: 11.15
During the past 13 years, the highest EV-to-EBITDA of United Therapeutics was 15.27. The lowest was -59.70. And the median was 7.14.
UTHR's EV-to-EBITDA is ranked better than 55.45% of 743
companies
in the Drug Manufacturers industry
Industry Median: 12.94
vs UTHR: 11.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
United Therapeutics (NAS:UTHR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
United Therapeutics's PE Ratio (TTM) for today is calculated as:
United Therapeutics's share price for today is $523.63.
United Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for United Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EV-to-EBITDA falls into.
United Therapeutics's current Enterprise Value is $19,105 Mil.
United Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,714 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (UTHR) has a EV-to-EBITDA of 11.15 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on United Therapeutics. This is 56% above median its historical median of 7.14. According to the industry distribution chart, United Therapeutics ranks #331 out of 743 companies in the Drug Manufacturers industry, placing it in the top 44.5%.
Is United Therapeutics' EV-to-EBITDA too high?
United Therapeutics' current EV-to-EBITDA of 11.15 is 56% above median its 10-year median of 7.14. The Drug Manufacturers industry median EV-to-EBITDA is 12.94. United Therapeutics' value of 11.15 is 13.8% below this industry median. Based on the distribution chart, United Therapeutics ranks #331 out of 743 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' EV-to-EBITDA compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #331 out of 743 companies for EV-to-EBITDA. This puts United Therapeutics in the upper half of its industry. The industry median EV-to-EBITDA is 12.94. United Therapeutics' value of 11.15 is 13.8% below this benchmark. While the company's 10-year median is 7.14 vs. the industry median of 12.94, United Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.94, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current EV-to-EBITDA of 11.15 is 13.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on United Therapeutics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current EV-to-EBITDA is 11.15, which is 56% above median its own 10-year median of 7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.24, compared to a current price of $523.63 — trading 35.2% above its estimated fair value. The current EV-to-EBITDA is 11.15, which is 56% above median its 10-year median of 7.14 and 13.8% below the Drug Manufacturers industry median of 12.94. United Therapeutics' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For United Therapeutics (UTHR), the current EV-to-EBITDA is 11.15 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $523.63 is trading 35.2% above its estimated GF Value™ of $387.24.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
EV-to-EBITDA: 11.15 (56% above median its 10-year median of 7.14)
GF Value™: $387.24 vs. price of $523.63 (35.2% above fair value)
Industry Position: 13.8% below the Drug Manufacturers median (#331 of 743)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
